<DOC>
	<DOCNO>NCT02193828</DOCNO>
	<brief_summary>The objective study assess safety effectiveness AA4500 treat palmar Dupuytren 's disease nodule .</brief_summary>
	<brief_title>Phase 2a Dose-Ranging Study Evaluate Safety Effectiveness AA4500 Treatment Dupuytren 's Disease Nodules</brief_title>
	<detailed_description>Approximately 13 site United States Australia , approximately 90 study subject . After pre-injection procedure complete day 1 , eligible men woman randomize 1:1:1 ratio dose group 4:1 ratio treatment group . Study drug administer palmar nodule locate select hand . AA4500 ( collagenase clostridium histolyticum ) 3 dos ( low , medium , high ) reconstitution sterile diluent ( 0.3 mg/mL calcium chloride dihydrate 0.9 % sodium chloride ) . Each dose study drug inject nodule . The injection administer 3 different volume accord randomization . Placebo reconstitution sterile diluent ( 0.3 mg/mL calcium chloride dihydrate 0.9 % sodium chloride ) . Each dose study drug inject nodule . The injection administer 3 different volume accord randomization . Follow visit evaluation safety efficacy require subject day 8 , 29 , 57 .</detailed_description>
	<mesh_term>Dupuytren Contracture</mesh_term>
	<criteria>1 . Provide sign date informed consent 2 . Be man woman ≥ 18 year age 3 . Have diagnosis Dupuytren 's disease AND least one palmar nodule select hand : 1 . Palpable 2 . Measures 0.5 cm 2.0 cm length 0.5 cm 2.0 cm width use handheld caliper n 3 . Not directly associate Dupuytren 's cord 4 . Have negative urine pregnancy test screen injection study drug use highly effective ( ie , &lt; 1 % failure rate ) contraception method judge investigator ( eg , abstinence , intrauterine device [ IUD ] , hormonal [ estrogen/progestin ] contraceptive , barrier control ) least one menstrual cycle prior study enrollment duration study surgically sterile ( female childbearing potential ) ; postmenopausal female ( menses least 1 year hysterectomy ) 5 . Be able comply study visit schedule specify protocol 1 . Received steroid injection ( eg , triamcinolone acetonide ) select nodule within 3 month administration study drug 2 . Has chronic muscular , neurological , neuromuscular disorder affect hand 3 . Has know systemic allergy collagenase excipient AA4500 4 . Has receive collagenase treatment ( eg , Santyl® ointment and/or XIAFLEX®/XIAPEX® ) within 30 day injection study drug hand select treatment 5 . Is currently receive plan receive anticoagulant medication receive anticoagulant medication ( except ≤ 150 mg aspirin daily ) within 7 day injection study drug 6 . Has know recent history stroke , bleeding , medical condition , investigator 's opinion would make subject unsuitable enrollment study 7 . Received investigational drug within 30 day injection study drug 8 . Is pregnant intend become pregnant study breastfeed child 9 . Has clinically significant medical history condition ( ) , include condition affect hand , would , opinion investigator , substantially increase risk associate subject 's participation protocol compromise scientific objective study 10 . Had surgery select hand within 3 month screen visit 11 . Has jewelry hand treat remove</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Dupuytren 's nodule</keyword>
</DOC>